Here, we initiate a preclinical study using murine BRAFWT murine B16-F10 melanoma and NRASmut 1014 melanoma cells to examine the effectiveness of combining the CXCR1/2 antagonist, SX-682, with the CDK4/6 inhibitor, palbociclib. Here, CXCR1 is linked to melanoma.